KEGG   DRUG: Tozinameran
Entry
D11971                      Drug                                   
Name
Tozinameran (JAN);
COVID-19 mRNA vaccine (nucleoside-modified);
Tozinameran and riltozinameran;
Tozinameran and famtozinameran;
Comirnaty (TN);
Pfizer-biontech Covid-19 vaccine (TN)
Product
  Other
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Therapeutic category: 6313
ATC code: J07BN01
Product: D11971<JP/US>
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Comment
Tozinameran is mRNA encoding full length of spike protein analog of SARS-CoV-2
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko05171  Coronavirus disease - COVID-19
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07B VIRAL VACCINES
    J07BN Covid-19 vaccines
     J07BN01 Covid-19, RNA-based vaccine
      D11971  Tozinameran (JAN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   COVID-19
    Pfizer-Biontech COVID-19 Vaccine
     D11971  Tozinameran (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   631  Vaccines
    6313  Viral vaccines
     D11971  Tozinameran (JAN)
Drug groups [BR:br08330]
 Antiviral
  DG03172  COVID-19 vaccine
   D11971  Tozinameran
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11971
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11971
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11971
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11971
Other DBs
CAS: 2417899-77-3
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system